Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05745857 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Oral Bevacizumab-800CW and Cetuximab-800CW Administration to Detect Early Esophageal Adenocarcinomas

Study acronym: SLURP
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 13, 2026 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status: Not Yet Recruiting to Recruiting Primary completion date: Dec 2024 to May 2026 · Start date changed from estimate of May 2023 to Sep 15, 2023 · Completion date: Dec 2024 to Dec 2026 · 1 morev2 Show 4 more changesShow less
    • Primary completion date: Dec 2024 to May 2026
    • Start date changed from estimate of May 2023 to Sep 15, 2023
    • Completion date: Dec 2024 to Dec 2026
    • Site details revised
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Previous studies have confirmed the great potential of quantitative fluorescence molecular endoscopy (qFME) when looking at additional lesion detection initially missed by high-definition white light endoscopy (HD-WLE) for surveillance of Barrett's esophagus.
Trial Details
NCT Number NCT05745857
Lead Sponsor University Medical Center Groningen
Conditions Barrett's Esophagus Without Dysplasia, Barrett Oesophagitis With Dysplasia, Esophageal Adenocarcinoma
Enrollment 25 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov